We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

131 hedge funds and large institutions have $1.68B invested in Arcus Biosciences in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 51 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

253% more call options, than puts

Call options by funds: $4.84M | Put options by funds: $1.37M

50% more funds holding in top 10

Funds holding in top 10: 6 → 9 (+3)

36% more capital invested

Capital invested by funds: $1.24B → $1.68B (+$445M)

13% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 15

4% more ownership

Funds ownership: 63.62% → 67.62% (+4%)

1% more funds holding

Funds holding: 130 → 131 (+1)

29% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 51

Holders
131
Holders Change
+1
Holders Change %
+0.77%
% of All Funds
2.29%
Holding in Top 10
9
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+50%
% of All Funds
0.16%
New
17
Increased
36
Reduced
51
Closed
15
Calls
$4.84M
Puts
$1.37M
Net Calls
+$3.47M
Net Calls Change
+$8.16M

Top Buyers

1
EC
EcoR1 Capital
California
+$55.6M
2
Franklin Resources
Franklin Resources
California
+$18.1M
3
BNP Paribas Asset Management
BNP Paribas Asset Management
France
+$14.7M
4
BCPEMI
Bain Capital Public Equity Management II
Massachusetts
+$14.2M
5
BI
BVF Inc
California
+$13.4M

Top Sellers

1
AI
Alphabet Inc
California
-$16M
2
Goldman Sachs
Goldman Sachs
New York
-$11.1M
3
State Street
State Street
Massachusetts
-$11M
4
Renaissance Technologies
Renaissance Technologies
New York
-$7.57M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$5.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$10.1M -$4.58M -147,031 -35%
Connor, Clark & Lunn Investment Management (CC&L)
27
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$9.51M +$121K +3,896 +1%
JP Morgan Chase
28
JP Morgan Chase
New York
$9.39M -$136K -4,374 -2%
PHP
29
Parkman Healthcare Partners
Connecticut
$8.25M -$311K -10,000 -4%
Invesco
30
Invesco
Georgia
$7.83M +$197K +6,331 +3%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$7.68M +$529K +16,982 +8%
Deutsche Bank
32
Deutsche Bank
Germany
$7.06M -$922K -29,637 -13%
D.E. Shaw & Co
33
D.E. Shaw & Co
New York
$6.73M -$5.04M -161,983 -46%
PAM
34
Panagora Asset Management
Massachusetts
$6.49M -$102K -3,276 -2%
Morgan Stanley
35
Morgan Stanley
New York
$4.67M -$4.22M -135,645 -50%
DCM
36
DAFNA Capital Management
California
$4.31M +$124K +4,000 +3%
GIM
37
Granahan Investment Management
Massachusetts
$3.66M +$3.26M +104,848 New
BG
38
Bellevue Group
Switzerland
$3.3M +$613K +19,700 +26%
AA
39
ALPS Advisors
Colorado
$3.05M -$187K -6,003 -6%
Swiss National Bank
40
Swiss National Bank
Switzerland
$3M – – –
PA
41
Parallel Advisors
California
$2.96M -$7.53K -242 -0.3%
Rafferty Asset Management
42
Rafferty Asset Management
New York
$2.87M -$699K -22,469 -21%
Adage Capital Partners
43
Adage Capital Partners
Massachusetts
$2.62M – – –
HM
44
HealthCor Management
New York
$2.44M +$2.18M +70,050 New
Bank of America
45
Bank of America
North Carolina
$2.39M +$992K +31,883 +87%
Two Sigma Investments
46
Two Sigma Investments
New York
$2.39M -$2.16M -69,307 -50%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$2.28M -$778 -25 -0%
Balyasny Asset Management
48
Balyasny Asset Management
Illinois
$2.26M -$55.2K -1,774 -3%
Citigroup
49
Citigroup
New York
$2.18M -$3.14M -100,784 -62%
PIM
50
Platinum Investment Management
Australia
$2.15M -$420K -13,510 -18%
1
2
3 4 5

RCUS Hedge Fund Activity: Q3 2021 in Review

131 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2021, worth a combined $1.68B — up 36% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new RCUS positions and 15 closed out — a net gain of 2 holders — while 36 added to existing stakes and 51 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $55.6M. The largest seller was Alphabet Inc, cutting an estimated $16M.

  • 131 institutional investors held Arcus Biosciences (RCUS) as of Q3 2021, up from 130 in Q2 2021.
  • Funds reported $1.68B of Arcus Biosciences stock for Q3 2021, up 36% quarter-over-quarter.
  • 17 funds opened new Arcus Biosciences positions in Q3 2021 and 15 closed out, a net change of +2 holders.
  • The largest Arcus Biosciences buyer in Q3 2021 was EcoR1 Capital, an estimated $55.6M added.
  • The largest Arcus Biosciences seller in Q3 2021 was Alphabet Inc, an estimated $16M sold.

Based on aggregated 13F filings for Q3 2021.